Ablacon, Inc is a software development firm that develops advanced mapping systems for the treatment of Atrial Fibrillation. The company announced that it has received Series A funding of $21.5 million through Ajax health for advancing its platform and to build a stronger, market-ready product. Ablacon’s unique Artificial Intelligence (AI) powered algorithm helps physicians precisely identify the drivers that cause Atrial Fibrillation — one of the most globally common cardiac ailments. Hyper-Optimized mapping ensures that cardiologists can better leverage catheter ablation therapy. Ablacon plans to utilize the funding towards making its technology better and to finance clinical trials for further extensive product testing.
“The Ablacon system is a very promising innovation in AFib mapping,” said Vivek Reddy, MD, the Helmsley Trust Professor of Medicine at the Icahn School of Medicine at Mount Sinai in New York City. “The early clinical experience indicates the tremendous promise of this technology to improve our ability to treat this challenging disease.”
“The idea to leverage techniques and algorithms from computer vision to analyze electric signals in the heart is ingenious. Ablacon combines concepts from both the medical world and machine intelligence in a way that I think is very promising,” said Leibniz Prize holder Daniel Cremers, Professor, and Chair for Computer Vision and Pattern Recognition at the Technical University of Munich.
“Since our first meeting with Ablacon, we have been impressed with the caliber of the team and the promise of the technology to improve patient care in AFib. I’m thrilled to join the team to advance this exciting project,” said Rohlen. Ablacon’s Founder and former CEO, Professor Peter Ruppersberg, will remain with the company as President and Chief Scientific Officer. “We look forward to working with Duke and his team of experienced healthcare executives to bring this technology to market,” said Ruppersberg.
Ajax health’s CEO, Duke Rohlen, will join Ablacon as Chairman and CEO, as a part of the investment.
Previously, Duke’s healthcare endeavors have been very rewarding from, some of which are –
- EPIX Therapeutics
- CV Ingenuity
- FoxHollow Technologies